MetaCap

Aligos Therapeutics (ALGS) vs IN8bio (INAB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

IN8bio (INAB) has outperformed Aligos Therapeutics (ALGS) over the past year, losing 55.4% versus a loss of 86.8%. Over five years, INAB leads with a -99.6% price change compared with -99.7% for ALGS. IN8bio is the larger company by market cap ($8.2 million vs $7.6 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ALGS-86.75%INAB-55.41%
+59%-17%-94%
Nov 21, 20251 yearNov 20, 2026
ALGS-99.69%INAB-99.63%
+7%-49%-105%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ALGS versus INAB key metrics
MetricALGSINAB
Share price$1.22$0.758
Market cap$7.62M$8.19M
1-day change-2.40%-1.86%
YTD return-86.91%-67.61%
1-year return-86.75%-55.41%
5-year return-99.70%-99.63%
EPS (TTM)$-6.46$-1.00
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$2.19M—
Revenue growth (YoY)-39.46%—
Net income (latest FY)$-24.19M$-19.44M
Operating margin-4024.93%—
Net margin-1106.72%—
52-week high$13.69$2.73
52-week low$1.18$0.724
Distance from 52-week high-91.09%-72.23%
Analyst consensusnonenone
Avg. price target upside+4193.44%+823.48%
Average volume57.37K120.61K
Shares outstanding5.45M10.81M
Employees8218
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • INAB has outperformed ALGS by 31.3 percentage points over the past year.

About Aligos Therapeutics

ALGS stock →

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 82 employees

About IN8bio

INAB stock →

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees

ALGS vs INAB FAQ

Which is bigger, Aligos Therapeutics or IN8bio?

IN8bio (INAB) is larger, with a market capitalization of $8.19M compared with $7.62M for Aligos Therapeutics (ALGS).

Which stock has performed better over the past year, ALGS or INAB?

INAB returned -55.41% over the past 12 months, compared with -86.75% for ALGS (price return, excluding dividends). Past performance does not predict future results.

Are Aligos Therapeutics and IN8bio in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons